PF-06835375

Phase 2Biologic

Pfizer

PF-06835375 is one of 81 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Immune ThrombocytopeniaActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Immune ThrombocytopeniaPhase 2

Active, not recruiting

Competition

Competitive Landscape

328 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Eptanemab

UCB

Phase 3

12 2

Olumiant

Eli Lilly

Phase 3

4 3

Stelara

Johnson & Johnson

Phase 3

3 4

Rinvoq

AbbVie

Phase 3

3 5

Gazyva

Roche

Phase 3

2 6

Cytoxan

BBaxter Healthcare Corporation

Phase 3

11 7

Intrarosa

Alnylam Pharmaceuticals

Phase 3

1 8

Rayos

RRoxane Laboratories

Phase 3

6 9

Depo-Provera

Cellcept

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Immune Thrombocytopenia

NCT05070845

Clinical

Trials by Indication[1]

Immune Thrombocytopenia1 trial

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Recruiting· Pfizer logo

Pfizer·Phase 2·NCT05070845·61 enrolled

Systemic Lupus Erythematosus1 trial

Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer·Phase 1·NCT03334851·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PF-06835375. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-06835375 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-06835375. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Pfizer

PF-06835375

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Immune Thrombocytopenia1 trial

Systemic Lupus Erythematosus1 trial

References

Drug Info

Quick Facts

Related News